BIQADX is a DPIIT-recognised deep-tech biomedical engineering venture reengineering diagnostics for the four billion people centralised healthcare never reaches. We unite reagent-free biotechnology, microfluidics, and edge intelligence into platforms that need no laboratory, no cold chain, and no reagents — so a fast, trustworthy answer can reach any patient, anywhere.
How we get there
Four frontier disciplines, engineered into a single diagnostic architecture — so the science always serves one purpose: a fast, trustworthy answer wherever a patient needs it, without reagents, cold chains, or a central laboratory.
Passive capillary-driven flow at the micron scale. No pumps, no valves — surface tension and channel geometry govern sample transport through sealed cartridge architectures.
Label-free voltammetric sensing reads charge-transfer dynamics of biomolecules directly on printed electrode arrays — bypassing conventional antibody-antigen wet chemistry entirely.
Multi-wavelength absorption spectroscopy captures the intrinsic spectral fingerprint of biological samples — haemoglobin fractions, bilirubin, lipid turbidity — without any reagent interaction.
Lightweight neural networks run locally on diagnostic micro-consoles. Signal classification, noise filtration, and anomaly detection happen entirely offline — zero cloud dependency.
Precision Biotechnology · Single-Cell Scale
Diagnosis begins where life does — at the scale of a single cell. We engineer platforms that read that biology directly, with no reagents and no laboratory in between.
Live · single-cell acquisitionReagent-Free Biotechnology · The Diagnostic Gap
At BIQADX, we believe the diagnostic gap is fundamentally a biomedical design problem. Conventional testing relies on fragile reagent chemistry, thermal cold chains, and complex lab infrastructure. We are bypass-engineering this complexity by integrating microfluidics, physical sensing modalities, and edge computation to read clinical signals directly from raw biological samples.
Our research spans microfluidic channel design, solid-state electrochemistry, and optical absorption spectroscopy. By replacing perishable wet chemistry with robust solid-state sensing, we are building diagnostic platforms that need no cold chain, no specialised operator, and no central laboratory — so frontline health workers can deliver lab-grade answers where patients actually are.
Biomedical R&D
A fully integrated diagnostic architecture combining microfluidics, multi-modal physical sensing, and autonomous edge intelligence — engineered to work without reagents, without connectivity, and without centralised labs.
We bypass conventional wet reagent chemistry by utilizing label-free spectroscopic and electrochemical sensing. By measuring the intrinsic optical absorption spectra and charge-transfer dynamics of biomolecules directly, we eliminate the need for perishable biochemical assays, costly enzymes, and cold-chain distribution. Diagnostics are transformed from a chemistry problem into a physics and data science problem.
Our sealed microfluidic carriers rely on passive capillary-driven flow and precise surface-tension gating. By engineering fluidic paths at the micron scale, we partition and process whole blood or saliva samples without active pumps, valves, or external moving parts. This robust physical architecture ensures sample integrity and consistent fluid dynamics even in non-laboratory, low-resource settings.
We integrate multiple sensing modalities — photonic transmission, electrochemical voltammetry, and thermal impedance — into a single solid-state analyzer. Reading these diverse physical parameters simultaneously from a single droplet generates a high-dimensional data signature of the sample. This multi-modal acquisition captures rich clinical markers that single-indicator tests completely miss.
To interpret high-dimensional biomolecular signals, our consoles run lightweight neural networks directly on the edge. Rather than transmitting raw clinical data to the cloud, machine learning models process sensor waveforms locally, performing real-time noise filtration, anomaly detection, and signature classification entirely offline. The console is fully self-contained and network-independent.
Traditional diagnostic plastic waste persists in the biosphere for centuries. Under patent application No. 202531060831, our EcoLabware program is engineering biodegradable, starch- and cellulose-based medical polymers that maintain sterile structural integrity during testing but degrade rapidly post-disposal. We treat the environmental footprint of a test as an engineering design constraint.
Diagnostics is not an accessory to medicine. It is the foundation on which every clinical decision stands — and four billion people do not have it.
The diagnostic portfolio
Evidence maturity
BIQADX is deliberately explicit about stage. The roadmap below separates what exists today from the evidence milestones required before clinical deployment.
Research, prototype, and engineering development. No product is clinically validated, regulatory-cleared, or commercially available.
Clinical need, architecture thesis, and design constraints defined.
Core invention directions captured through applications under examination.
Physical systems and sealed carriers iterated through engineering builds.
Planned bench evidence against reference methods and performance targets.
Future human-subject studies under approved protocols and comparators.
Future submissions, quality-system evidence, and deployment governance.
Honest by design
A DPIIT-recognised deep-tech startup registered in Bihar and New Delhi, India. A team of founders building diagnostic technology from first principles. Holders of multiple Indian patent applications, including lead application No. 202531060831, filed and under examination at the Indian Patent Office. Producers of engineering blueprints, prototypes, and extensive scientific and technical documentation. Mission-driven, IP-anchored, and early-stage by choice.
We do not have clinically validated products. We do not have regulatory approvals. We do not have commercial revenue. We have not conducted human-subject clinical trials. Every product on this site is at a research, concept, prototype, or engineering-development stage. We show our stage on every page because honesty at this phase earns the trust that matters at the next one.
From the journal
Choose your path
Review the thesis, stage, IP posture, and diligence pathway for mission-aligned capital.
Investor brief →Understand how decentralised diagnostics could support frontline access, surveillance, and last-mile programs.
Impact pathway →Explore the evidence architecture, validation roadmap, and future collaboration areas.
Evidence roadmap →Join a small deep-tech team building across physics, biology, engineering, materials, and AI.
Open roles →Inside BIQADX
A small, multidisciplinary team working across biology, engineering, materials, and AI — doing the careful, unglamorous bench work that earns trust one experiment at a time.
